A study to evaluate a facial cream containing 0.5% bakuchiol on subjects with acne

A pilot, open-label study to evaluate the antimicrobial and anti-inflammatory properties of UP256 cream

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13992386

Enrollment

Registered

2020-09-11

Start date

2009-04-17

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne and hyperpigmentation Skin and Connective Tissue Diseases Acne

Interventions

A cream containing 0.5% bakuchiol was applied to the face twice a day for a period of 12 weeks. The study was open-label and no control group or placebo was used. Participants that met the inclusion c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female 2. Moderate to mild acne 3. Age 12-30 4. Fitzpatrick Skin Type III and higher

Exclusion criteria

Exclusion criteria: 1. Not healthy 2. Severe acne 3. Recent use of acne treatment

Design outcomes

Primary

Measure	Time frame
1. Acne inflammatory lesions and non-inflammatory lesions measured using lesion count at baseline and weeks 4, 8, and 12 2. Post-inflammatory hyperpigmentation caused by acne measured using physician assessment method at baseline and weeks 4, 8, and 12	—

Secondary

Measure	Time frame
Safety and tolerability of the cream measured by investigator assessment of erythema (redness), dryness, peeling and oiliness at baseline and weeks 1, 2, 4, 6, 8, 10 and 12	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 16, 2026